Sublethal hemorrhage blunts the inflammatory cytokine response to endotoxin in a rat model

Journal of Trauma - Injury, Infection and Critical Care

Volumn 46, Issue 1, 1999, Pages 145-149

  Zervos, Emmanuel E ^a,b   Kramer, Andrew A ^a   Salhab, Khaled F ^a   Norman, James G ^a   Carey, Larry C ^a   Rosemnrgy, Alexander S ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b TAMPA GENERAL HOSPITAL   (United States)

Author keywords

Cytokine; mRNA; Sepsis

Indexed keywords

INTERLEUKIN 1; MESSENGER RNA; TUMOR NECROSIS FACTOR;

BLEEDING; CONFERENCE PAPER; CYTOKINE PRODUCTION; DOSE RESPONSE; ENDOTOXEMIA; GENE EXPRESSION REGULATION; INFLAMMATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALIDATION PROCESS;

EID: 0032920266     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-199901000-00025     Document Type: Conference Paper

References (37)

1. Ertel W, Morrison M, Meldrum DR, et al. Ibuprofen restores cellular immunity and decreases susceptibility to sepsis following hemorrhage. J Surg Res. 1992;63:55.
2. Zhu X, Zelhveger R, Zhu X, et al. Cytokine gene expression in splenic macrophages and Kupffer cells following hemorrhage. Cytokine. 1995;7:8.
3. Marks J, Marks CB, Luce JM, et al. Plasma tumor necrosis factor in patients with septic shock. Am J Respir Dis. 1990; 141:94.
4. Hack CE, DeGroot ER, Felt-Bersma RJF, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989; 74:1704.
5. Damas P, Reuter A, Gysen P, et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med. 1989; 17:975.
6. Abraham E, Jesmok G, Tuder R, et al. Contribution of tumor necrosis factor to pulmonary cytokine expression and lung injury after hemorrhage and resuscitation. Crit Care Med. 1995;23:1319.
7. Shenkar R, Coulson W, Abraham E. Hemorrhage and resuscitation induce alterations in cytokine expression and the development of acute lung injury. Am J Rcspir Cell Mol Biol 1994;10:290.
8. Abraham E, Coulson W, Schwartz M, et al. Effects of therapy with soluble tumor necrosis factor receptor fusion protein on pulmonary cytokine expression and lung injury following hemorrhage and resuscitation. Clin Exp Immunol. 1994;98:29.
9. Ferrari-Baliviera E, Mealy K, Smith R, et al. Tumor necrosis factor induces adult respiratory distress syndrome in rats. Arch Surg. 1989;124:1400.
10. Demeure EJ, Paleocene J, Lee R. Hemorrhagic shock in endotoxin-resistant mice: improved survival unrelated to deficient production of tumor necrosis factor. J Trauma. 1993;35:720.
11. Abraham E, Bürsten S, Shenkar S, et al. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med. 1995:2:569.
12. Schmand JF, Ayala A, Chaudry IH. Effects of trauma, duration of hypotension, and resuscitation regimen on cellular immunity after hemorrhagic shock. Crit Care Med. 1994;22:1076.
13. Sanchez-Cantu L, Rode LIN, Yun TJ, et al. Tumor necrosis factor alone does not explain the lethal effect of lipopolysaccharide. Arch Surg. 1990;126:231.
14. Scatter SC, Bennet T, Li MH, et al. Macrophage endotoxin tolerance: tumor necrosis factor and interleukin-1 regulation by lipopolysaccharide pretreatment. Arch Surg. 1994; 129:1263.
15. Baker CC, Niven-Fairchild T, Caragnano C, et al. Outcome following femur fracture and subsequent cecal ligation and puncture in endotoxin-sensitive (C3H/HeN) and endotoxin resistant (C3H/HeJ) mice. J Surg Res. 1991 ;50:170.
16. Cable A, Fitting C, Farkas JC, et al. Influence of surgery on in-vitro cytokine production by human monocytes. Cytokine. 1992;4:576.
17. Horton J. The cardiocirculatory and metabolic effects of endotoxin challenge after canine resuscitated hemorrhagic shock. J Trauma. 1989:29:195.
18. Tumbull AG, Talbot JA, Hamilton SM. Hemodynamic changes and gut barrier function in sequential hemorrhagic and endotoxic shock. J Trauma. 1993;38:705.
19. Ertel W, Morrison MH, Ayala A, et al. Interferon-γ attenuates hemorrhage-induced suppression of macrophage and splenocyte functions and decreases susceptibility to sepsis. Surgery. 1992;111:177.
20. Myers SI, Tumage RH, Kadesky KM, et al. Endotoxic shock after long-term resuscitation of hemorrhage/reperfusion injury decreased splanchnic blood flow and eicosanoid release. Ann Surg. 1996;224:213.
21. Livingston DH, Wang MT, Hsieh J, et al. Hemorrhagic shock inhibits lipopolysaccharide induced myelopoiesis in both germ-free and conventional rats. Surgery. 1992; 112:773.
22. Faist E, Mewes A, Strasser T, et al. Alteration of monocyte function following major injury. Arch Surg. 1988;123:287.
23. West MA, Li MH, Scatter SC, et al. Pre-exposure to hypoxia or septic stimuli differentially regulated endotoxin release of tumor necrosis factor, interleukin-6, interleukin-l, prostaglandin E2, nitric oxide, and Superoxide by macrophages. J Trauma. 1994;37:82.
24. Zervos EE, Norman JG, Carey LC, Rosemurgy AS. Cytokine activation through sublethal hemorrhage is protective against early, lethal endotoxic challenge. Arch Sitrg. 1997;132:1216.
25. Norman JG, Fink GW, Franz MG. Acute pancreatitis induced intrapancreatic TNF gene expression. Arch Surg. 1995;130:966.
26. Ohlsson K, Bjok P, Bergefeldt M, et al. An interleukin-l receptor antagonist reduces mortality from endotoxic shock. Nature. 1990;348:550.
27. Wakabayashi G, Gelfand JA, Burke IF, et al. A specific antagonist for interleukin-l prevents E. coli induced shock in rabbits. FASEB J. 1991;5:338.
28. Zingarelli B, Squadrito F, Altavilla D, et al. Role of tumor necrosis factor alpha in acute hypovolemic hemorrhagic shock in rats. Am J Physiol. 1994;266:H1512.
29. Shenkar R, Coulson WF, Abraham E. Anti-transforming growth factor beta monoclonal antibodies prevent lung injury in hemorrhaged mice. Am J Respir Cell Mol Biol. 1994;11:351.
30. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to TNF in patients with sepsis syndrome. JAMA. 1995;273:931.
31. Fischer CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin one receptor antagonist in the treatment of patents with sepsis syndrome: results from a randomized double blind placebo controlled trial. JAMA. 1994;271:1836.
32. Dhainaut JF, Tenaillon A, LeTulzo Y, et al. Platelet activating factor receptor antagonist BN-52021 in the treatment of severe sepsis: a randomized, double blind, placebo controlled multicenter trial. Crit Care Med. 1994; 22:1720.
33. Dhainaut JF, Tanaillon A, Hemmer M, et al. Confirming phase III clinical trial to study the efficacy of a platelet activating factor antagonist, BN 52021, in reducing mortality of patients with severe gram negative sepsis. Am J Respir Crit Care Med. 1995;151:A447.
34. Gavin TJ, Fabian TC, Wilson JD, et al. Splanchnic and systemic hemodynamic response to portal vein endotoxin after resuscitation from hemorrhagic shock. Surgery. 1994; 115:310.
35. Kovacs EJ, Radzioch D, Young HA, et al. Differential inhibition of IL-1 and TNF mRNA expression by agents which block second messenger pathways in murine macrophages. J Immunol. 1988;141:3101.
36. Spengler RN, Spengler ML, Stricter RM, et al. Modulation of tumor necrosis factor alpha gene expression: desensitization of prostaglandin E2 induced suppression. J Immunol. 1989; 142:4346.
37. Endres S, Cannon JG, Ghorbani R, et al. In vitro production of IL-lb, IL-la, TNF and IL-2 in healthy subjects: distribution effect of cyclooxygenase inhibition and evidence of independent gene regulation. Ear J Immunol. 1989; 19:2327.